Comparative Pharmacology
Head-to-head clinical analysis: SODIUM OXYBATE versus XYWAV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM OXYBATE versus XYWAV.
SODIUM OXYBATE vs XYWAV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gamma-hydroxybutyrate (GHB) receptor agonist; modulates GABA-B and GHB receptors, increasing slow-wave sleep and reducing cataplexy.
XYWAV (calcium, magnesium, potassium, and sodium oxybates) is a mixture of oxybate salts. The exact mechanism of action is unknown, but it is thought to involve modulation of GABA-B receptors and possibly GHB receptors, leading to increased slow-wave sleep and reduced cataplexy.
Oral: 4.5 g to 9 g per day divided into two equal doses of 2.25 g to 4.5 g taken at bedtime and again 2.5 to 4 hours later. Maximum single dose: 4.5 g, maximum total daily dose: 9 g.
Oral, starting dose 2.25 g twice nightly, titrated weekly by 0.75 g per dose up to a maximum of 4.5 g twice nightly. Administer first dose at bedtime, second dose 2.5–4 hours later.
None Documented
None Documented
Clinical Note
moderateSodium oxybate + Venlafaxine
"The risk or severity of adverse effects can be increased when Sodium oxybate is combined with Venlafaxine."
Clinical Note
moderateSodium oxybate + Nefazodone
"The risk or severity of adverse effects can be increased when Sodium oxybate is combined with Nefazodone."
Clinical Note
moderateSodium oxybate + Sertraline
"The risk or severity of adverse effects can be increased when Sodium oxybate is combined with Sertraline."
Clinical Note
moderate0.5–1 hour; clinical context: rapid elimination necessitates multiple nightly doses in narcolepsy.
Terminal half-life is approximately 1 hour (range 0.5–1.5 hours) for oxybate (GHB) component; the mixed salts formulation does not alter elimination. Short half-life necessitates twice-nightly dosing for sustained sleep.
Primarily renal; >80% of dose excreted as carbon dioxide via expiration, <5% unchanged in urine; minor fecal elimination.
Primarily renal; >95% of the dose is eliminated as metabolites (3-hydroxypropionic acid, 4,5-dihydroxyhexanoic acid) and <5% as unchanged drug via urine. Fecal excretion accounts for <1%.
Category D/X
Category C
CNS Depressant
CNS Depressant / Narcolepsy Agent
Sodium oxybate + Paroxetine
"The risk or severity of adverse effects can be increased when Sodium oxybate is combined with Paroxetine."